Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
2.260
-0.280 (-11.02%)
At close: Nov 20, 2024, 4:00 PM
2.270
+0.010 (0.44%)
After-hours: Nov 20, 2024, 7:58 PM EST
Cabaletta Bio Employees
As of December 31, 2023, Cabaletta Bio had 103 total employees, including 101 full-time and 2 part-time employees. The number of employees increased by 43 or 71.67% compared to the previous year.
Employees
103
Change (1Y)
43
Growth (1Y)
71.67%
Revenue / Employee
n/a
Profits / Employee
-$1,011,301
Market Cap
110.46M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103 | 43 | 71.67% |
Dec 31, 2022 | 60 | 6 | 11.11% |
Dec 31, 2021 | 54 | 20 | 58.82% |
Dec 31, 2020 | 34 | 12 | 54.55% |
Dec 31, 2019 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Puma Biotechnology | 185 |
Compugen | 68 |
Acumen Pharmaceuticals | 52 |
Candel Therapeutics | 42 |
Cardiff Oncology | 32 |
Zentek | 24 |
Avalo Therapeutics | 19 |
Inhibikase Therapeutics | 9 |
CABA News
- 4 weeks ago - Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
- 2 months ago - Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - GlobeNewsWire
- 3 months ago - Cabaletta Bio to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 3 months ago - Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum - GlobeNewsWire
- 5 months ago - Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment - Seeking Alpha
- 5 months ago - Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 - GlobeNewsWire
- 6 months ago - Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire